Mark Blumenkranz

Mark Blumenkranz

Director/Board Member en KALA BIO, INC. .

Fortuna: 46 261 $ al 29/02/2024

73 años
Health Technology
Consumer Services
Finance

Perfil

Mark S.
Blumenkranz
, M.D., MMS, is HJ Smead Professor in the Department of Ophthalmology at Stanford University.
He received his Undergraduate, Masters degree in biochemical pharmacology, and MD at Brown, Ophthalmic residency training at Stanford, and a Fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute.
? He was a director of Oculex Pharmaceuticals, a privately held pharmaceutical company that pioneered the use of bio-erodable polymers for extended release of ocular steroids.
At Oculex he was also Chairman of the SAB and the principal designer of the successful phase 2 Ozurdex trial, leading to its acquisition by Allergan in 2003.
He served as a co-founder, Director and Chairman of the SAB of Macusight, an ophthalmic pharmaceutical company developing proprietary mTor inhibitors for ophthalmic disease, which was acquired by Santen in 2010.
He was a founder and director of Peak Surgical, an innovator in pulsed plasma mediated electro-surgery that was acquired by Medtronics in 2011.
In 2004 he co-founded Optimedica Corporation for which he co-wrote the foundation IP for the PASCAL and Catalys lasers, and which was acquired by AMO in 2013.
In 2006 co-founded Adverum Biotechnologies (ADVM; NASDAQ) a gene therapy company and served as Chairman of the Board until 2016.
He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015.
He is a co-founder and serves as a director of Digisight Corporation, a venture financed ophthalmic digital health company and Lagunita Biosciences LLC an early stage biotechnology and medical investment company.
?

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
22/06/2023 6 443 ( 0.24% ) 46 261 $ 29/02/2024

Cargos activos de Mark Blumenkranz

EmpresasCargoInicio
KALA BIO, INC. Director/Board Member 15/11/2021
Oculogics, Inc. Director/Board Member -
Founder 01/10/2015
Director/Board Member 27/02/2019
Director/Board Member -
Stanford University Corporate Officer/Principal 01/01/1997
Combangio Corp. Director/Board Member -
Director/Board Member -
Consultant / Advisor -
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Todos los cargos activos de Mark Blumenkranz

Antiguos cargos conocidos de Mark Blumenkranz.

EmpresasCargoFin
░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░ ░░░░░░░░ -
░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░
Ver el detalle de la experiencia de Mark Blumenkranz.

Formación de Mark Blumenkranz.

Brown University Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Mark Blumenkranz.

Relaciones

100 +

Relaciones de 1er grado

35

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas3
KALA BIO, INC.

Health Technology

ADVERUM BIOTECHNOLOGIES, INC.

Health Technology

PRESBIA PLC

Health Technology

Empresas privadas29

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Finance

Association of University Professors of Ophthalmology

Macula Society

Health Technology

The Retina Society

Midlab, Inc.

Health Technology

Commercial Services

Byers Eye Institute

Health Technology

Health Technology

Technology Services

Oculogics, Inc.

Health Technology

Finance

Health Technology

Health Technology

Retinal Degeneration Fund

Finance

Commercial Services

Combangio Corp.

Ver las conexiones de la empresa
  1. Bolsa
  2. Insiders
  3. Mark Blumenkranz